2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | -$69M | 0.0% | -623.6% | -$77M | — | $44M |
| 2024 | $7M | -$67M | 0.0% | -1000.2% | -$58M | — | $16M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$22M | — | — | -$28M | — | $48M |
| Dec '25 | $0 | -$28M | — | — | -$17M | — | $44M |
| Sep '25 | $10M | -$12M | 0.0% | -133.3% | — | — | $27M |
| Mar '25 | $3M | -$15M | 0.0% | -501.1% | -$24M | — | $6M |
| Dec '24 | $0 | -$21M | — | — | -$19M | — | $16M |
| Sep '24 | — | -$16M | — | — | — | — | $18M |
How the market has priced EVMN against its own fundamentals since 2025-11 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 1 years, Evommune, Inc.'s revenue has grown 85.7% per year. These are computed facts, not advice.
As of FY2025, Evommune, Inc. reported — of total debt against $44M of cash.
In FY2025, gross margin was —, operating margin -623.6%, and net margin -529.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.